As such, studying HMGA2 as a predictive biomarker for metastasis and treatment resistance in CRC is critical to obtain further insight into its pathogenic properties and its roles in sustaining genome instability, disease progression and metastasis, as it may ultimately serve as a target for personalized therapeutic intervention. Here, HMGA2 is linked to colorectal carcinoma.